Under the agreement, Idera exclusively licensed the therapeutic oncology applications, excluding cancer vaccines, of its lead TLR9 agonists, IMO-2055 and IMO-2125. With the grant of HSR clearance, the agreement is now in effect and Idera is entitled to receive an upfront licensing fee of $40 million from Merck KGaA.